Editas Medicine Announces First Quarter 2025 Results and Business Updates
Provided By GlobeNewswire
Last update: May 12, 2025
Company to share in vivo preclinical data demonstrating the successful use of targeted lipid nanoparticles to deliver HBG1/2 promoter editing cargo to hematopoietic stem and progenitor cells (HSPCs) at ASGCT this week
Read more at globenewswire.com
